Wednesday, March 29, 2023


Biotechnology News Magazine

ImmPACT Bio Appoints Biren Amin, M.B.A. to its Board of Directors

Latest Posts

Risk From Pharma Reps Using Unapproved Content and Messaging in the Field Persists, but a Focus on Training Could Be the Answer

ACTO advises Study Reveals 50% of respondents in leadership roles catch incidents of field reps using unapproved content, but a continuous learning culture could eliminate this behavior.

Entrinsic Bioscience® Expands enterade® Brand with Innovative Approach to the Dietary Support of Irritable Bowel Syndrome with Diarrhea (IBS-D

enterade® IBS-D is the first medical food formulated with plant-based amino acids and electrolytes for Irritable Bowel Syndrome with Diarrhea (IBS-D)-

Russell Finex Helps Leading Pharmaceutical Company Meet High Levels Of Demand With The Russell Compact Sieve

To ensure the highest quality final product, the company reached out to Russell Finex for a high-capacity vibrating screen. After assessing the company’s requirements, Russell Finex recommended the Russell Compact Sieve® as the ideal solution for check-screening pharmaceutical powders due to its stainless-steel contact parts, and easy-to-clean strip down design.

How Biotech Businesses Can Benefit from Freelance Experts

Ashmita Das, CEO of open talent platform Kolabtree, shares some of Kolabtree freelancer’s success stories.

ImmPACT Bio USA, Inc. (“ImmPACT Bio”), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for treating cancer, today announced the appointment of Biren Amin, M.B.A., to its board of directors.

Biren Amin has been the chief financial officer (CFO) and chief strategy officer of Pyramid Biosciences, Inc. since August 2022. He also serves as a co-director on the board of trustees of Axiom REACH Foundation, a non-profit organization focused on addressing public health disparities.

Sheila Gujrathi, M.D., chair of ImmPACT Bio’s board of directors said:

“It is my pleasure to welcome Biren to the board of ImmPACT Bio. Biren Amin is a seasoned executive who is highly experienced in capital markets, finance, and corporate strategy. Biren’s broad and deep expertise will be invaluable as we continue to build the company to advance our pipeline of next-generation CAR T-cell therapies.”

“This year we are rapidly advancing our novel bispecific CAR to treat aggressive B-cell lymphoma into Phase 1/2 clinical trials,” said Sumant Ramachandra, M.D., Ph.D., president and chief executive officer of ImmPACT Bio. “Biren’s world-class experience in the cell therapy space as a biotechnology equity analyst at a top investment bank, along with his knowledge of finance and capital markets, will help us implement robust strategies to grow the company and move our next-generation CAR T-cell therapies through the clinic and ultimately to patients.”

“ImmPACT Bio’s portfolio of logic-gate-based CAR T-cell therapies holds tremendous potential to transform how we treat cancers,” said Mr. Amin. “I am excited to work with this dynamic board and talented leadership team to help ImmPACT Bio achieve its vision of developing transformative oncology medicines for cancer patients who are in desperate need of new treatment options.”

Previously, Mr. Amin was CFO of Immuneering Corporation and led its IPO in mid-2021. Before his pivot to industry, Mr. Amin spent nearly two decades on Wall Street building a strong track record covering small and mid-cap biotechnology companies. He was managing director and senior biotechnology analyst at Jefferies Financial Group and earned industry recognition from Financial Times/StarMine and Institutional Investor. Earlier in his career, Mr. Amin held positions within business development and medical affairs functions at Aventis Pharmaceuticals. He holds an M.B.A. from the Stern School of Business at New York University and earned his M.S. in pharmacy from Long Island University, and a B.S. in pharmacy from the University of Sciences in Philadelphia.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine